Unknown

Dataset Information

0

Targeting Amyloidogenic Processing of APP in Alzheimer's Disease.

ABSTRACT: Alzheimer's disease (AD) is the most common type of senile dementia, characterized by neurofibrillary tangle and amyloid plaque in brain pathology. Major efforts in AD drug were devoted to the interference with the production and accumulation of amyloid-? peptide (A?), which plays a causal role in the pathogenesis of AD. A? is generated from amyloid precursor protein (APP), by consecutive cleavage by ?-secretase and ?-secretase. Therefore, ?-secretase and ?-secretase inhibition have been the focus for AD drug discovery efforts for amyloid reduction. Here, we review ?-secretase inhibitors and ?-secretase inhibitors/modulators, and their efficacies in clinical trials. In addition, we discussed the novel concept of specifically targeting the ?-secretase substrate APP. Targeting amyloidogenic processing of APP is still a fundamentally sound strategy to develop disease-modifying AD therapies and recent advance in ?-secretase/APP complex structure provides new opportunities in designing selective inhibitors/modulators for AD.

SUBMITTER: Zhao J 

PROVIDER: S-EPMC7418514 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Targeting Amyloidogenic Processing of APP in Alzheimer's Disease.

Zhao Jing J   Liu Xinyue X   Xia Weiming W   Zhang Yingkai Y   Wang Chunyu C  

Frontiers in molecular neuroscience 20200804

Alzheimer's disease (AD) is the most common type of senile dementia, characterized by neurofibrillary tangle and amyloid plaque in brain pathology. Major efforts in AD drug were devoted to the interference with the production and accumulation of amyloid-β peptide (Aβ), which plays a causal role in the pathogenesis of AD. Aβ is generated from amyloid precursor protein (APP), by consecutive cleavage by β-secretase and γ-secretase. Therefore, β-secretase and γ-secretase inhibition have been the foc  ...[more]

Similar Datasets

Unknown miR-143-3p Inhibits Aberrant Tau Phosphorylation and Amyloidogenic Processing of APP by Directly Targeting DAPK1 in Alzheimer's Disease.
| S-EPMC9317260 | biostudies-literature
Unknown Involvement of receptor tyrosine kinase Tyro3 in amyloidogenic APP processing and β-amyloid deposition in Alzheimer's disease models.
| S-EPMC3372537 | biostudies-literature
Unknown Alteration in synaptic nanoscale organization dictates amyloidogenic processing in Alzheimer's disease.
| S-EPMC7773964 | biostudies-literature
Unknown Multi-compartmental modeling of SORLA's influence on amyloidogenic processing in Alzheimer's disease.
| S-EPMC3483162 | biostudies-literature
Unknown The acute phase protein lactoferrin is a key feature of Alzheimer's disease and predictor of Aβ burden through induction of APP amyloidogenic processing.
| S-EPMC8758478 | biostudies-literature
Unknown Quantitative modelling of amyloidogenic processing and its influence by SORLA in Alzheimer's disease.
| S-EPMC3252570 | biostudies-literature
Unknown APP overexpression in the absence of NPC1 exacerbates metabolism of amyloidogenic proteins of Alzheimer's disease.
| S-EPMC4654063 | biostudies-literature
Unknown Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease.
| S-EPMC3065534 | biostudies-literature
Unknown Plasmalogens inhibit APP processing by directly affecting ?-secretase activity in Alzheimer's disease.
| S-EPMC3322458 | biostudies-literature
Unknown Increased amyloidogenic processing of transgenic human APP in X11-like deficient mouse brain.
| S-EPMC2949864 | biostudies-other